Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xilio Therapeutics, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing masked immuno-oncology therapies. Its 8-K reports cover financial results, pipeline and business updates, investor presentations, material agreements, capital-structure matters, and clinical or regulatory disclosures tied to its masked I-O programs.
Proxy statements and related 8-K filings describe stockholder votes, director elections, board and committee changes, auditor ratification, equity incentive plans, and amendments affecting common stock. The filing record also includes disclosures related to reverse stock split matters, security-holder rights, director compensation, and governance arrangements for the company’s Delaware corporate structure.
Xilio Therapeutics director Bello Akintunde Olatokumbo received a grant of stock options for 5,000 shares of common stock. The options carry an exercise price of 7.99 per share and expire on June 10, 2036.
The award will vest as to 100% of the underlying 5,000 shares on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders following the grant date, subject to his continued service. Following this grant, he holds 5,000 stock options, reflecting a routine compensation-related equity award rather than an open-market purchase or sale.
Xilio Therapeutics director Shannon James Samuel received a grant of stock options for 5,000 shares of common stock at an exercise price of $7.99 per share. These options vest 100% on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, contingent on continued service.
Following the grant, Samuel holds 5,000 options directly.
Xilio Therapeutics director Daniel J. Curran received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and bring his total option holdings reported in this filing to 5,000 derivative shares.
The award was granted as of June 11, 2026 and will vest as to 100% of the underlying shares on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders following the grant date, provided he continues to serve the company through the vesting date. This is a compensation-related grant rather than an open-market purchase or sale.
Xilio Therapeutics director Xu Yuan received a grant of stock options as equity compensation. The award covers 5,000 options to buy common stock at an exercise price of $7.99 per share, expiring on June 10, 2036.
The options were granted on June 11, 2026 and will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting after the grant date, as long as Xu Yuan continues to serve the company through that vesting date. After this grant, the filing shows Xu Yuan holding 5,000 derivative securities (stock options).
Xilio Therapeutics director Robert W. Ross received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $7.99 per share and expires on June 10, 2036. It will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, assuming he remains in service. This is a compensation-related award, not an open-market share purchase or sale.
Xilio Therapeutics director Sara Bonstein received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $7.99 per share and expire on June 10, 2036. They vest 100% on June 11, 2027 or at the next annual stockholder meeting, whichever occurs first, assuming continued service.
Xilio Therapeutics director Aoife Brennan received a new stock option grant. The award covers 5,000 shares of common stock at an exercise price of $7.99 per share, expiring on June 10, 2036. It vests 100% on June 11, 2027 or at the next annual stockholder meeting, subject to continued service.
Xilio Therapeutics, Inc. reported governance and compensation updates from its 2026 annual stockholder meeting. To rebalance its staggered board, Daniel Curran, M.D. resigned as a Class II director immediately after being re-elected and was reappointed as a Class III director with no changes to his compensation.
Stockholders elected four Class II directors—Akintunde Bello, Ph.D., Dr. Curran, Robert Ross, M.D., and Yuan Xu, Ph.D.—to terms expiring at the 2029 annual meeting. They also ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan so that shares underlying outstanding prefunded warrants are included with outstanding common stock when calculating the plan’s annual evergreen increase, potentially affecting future equity award capacity.
Xilio Therapeutics, Inc. filed Amendment No. 1 to its shelf registration (Form S-3/A) to update the registration following subsequent sales under a prior shelf and to refresh exhibits. The registration statement provides a base shelf permitting up to $250,000,000 of securities and a sales agreement prospectus for up to $14,500,000 of common stock to be sold under an at-the-market agreement with Leerink Partners LLC.
The amendment discloses that the company issued and sold $4,596,248 of securities under a prior S-3 (File No. 333-285703), updates the filing fee table, revises the public float calculation and prospectus exhibits (legal opinion and auditor consent), and supplies the base prospectus text describing possible securities, plan of distribution, and risk factors. The filing states a public float of $57,598,009 based on 6,575,139 shares outstanding as of May 26, 2026, and includes referenced prices of $8.35 (May 26, 2026 last sale) and $8.81 (price used for a prior calculation).